Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease.
Industry: Health Care
Latest Trade: $1.02 0.00 (0.0%)
First Day Return: +2.7%
Return from IPO: -93.2%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 03/04/2022 |
Offer Price | $15.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 4.6 |
Deal Size ($mm) | $69 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/24/2022 |
Offer Price | $15.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 4.6 |
Deal Size ($mm) | $69 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
TD Cowen |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Menlo Park, CA, United States |
Founded | 2017 |
Employees at IPO | 22 |
Website www.an2therapeutics.com |